News Hub | News Direct

Colorado Has Just Legalized The Use of Magic Mushrooms

MarketJar

Psychoactive medicine has come a long way in the last couple of years and is not slowing down anytime soon. Gone are the days when hallucinogens conjured up images of tie-dye T-shirts and peace signs. The psychoactive renaissance taking place right now is fueled by governments, science, celebrities and big-time investors. The worsening mental health and substance-abuse crises and the clear benefits of psychoactive-assisted therapy to combat these issues are becoming too big to ignore, creating an unstoppable shift in the way society views psychoactives. Colorado, a pioneer in the recreational MJ space, just became the second state to decriminalize and legalize the use of psychoactives for recreational purposes. Voters passed a ballot initiative during the mid-term election to make it legal for adults to purchase and use psychoactives. Colorado’s bill is creating a domino effect. Right now there are at least 20 different US states and cities working towards decriminalizing the substances. And things could soon reach the federal level. In July, Joe Biden said that he expects regulators to approve psychoactives within the next two years to treat PTSD and depression. Canada is also making strides in legalization. In October, Alberta made history by becoming the first province to regulate psychoactives for the treatment of mental health conditions. The Province’s new regulatory framework is due to take effect January 2023. These changes in regulations come at a time when the national mental health crisis is worsening and in turn, more people are seeking help from alternative treatment providers. According to John Hopkins Medicine, 26% of Americans age 18 and over suffer from a diagnosable mental disorder in a given year, while over 6.7 million people in Canada struggle with mental health issues or illnesses. As psychoactives gain more acceptance, companies within the market stand to benefit, particularly those offering high-quality products and integrated mental health care treatment options at clinics. Leading integrated mental healthcare company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) is focused on the development and delivery of innovative mental health care and access to safe, evidence-based psychoactive-assisted therapies. Numinus has continued to expand its mental health service offerings as well as its network of wellness clinics across Canada and the US. Numinus has already experienced noteworthy revenue growth in Q3 2022, growing nearly 32% year-over-year (YoY), which was primarily driven by the acquisitions of the Neurology Centre of Toronto and Mindspace. The company also saw its gross margin grow by 24.4% in Q3, compared to -2.8% YoY. And with the acquisition of Novamind, which closed in June 2022, Numinus is now one of the highest revenue-producing mental healthcare companies providing psychoactive-assisted therapies, with over $12 million of combined proforma annual revenues. The company will be releasing its fourth quarter 2022 results on November 29 and according to Numinus founder and CEO Payton Nyquvest, Q4 will be “the first quarter demonstrating the power of its larger, cross-border platform." Numinus Wellness also recently launched its Ketamine for Chronic and Serious Medical Illness Program. This new program will first be implemented in Numinus clinics in Utah, British Columbia, and Quebec. The company plans to expand the program to other clinics in the coming months. Numinus' program will include psychoactive-assisted therapy along with additional community support to alleviate patients' physical, emotional, mental, and spiritual suffering and care from healthcare professionals who specialize in severe and chronic medical illnesses. As Oregon and Colorado have now legalized psychoactives, the Biden administration is working to get psilocybin federally approved within the next two years as clinical evidence of their effectiveness in treating mental health disorders grows. It’s only a matter of time and Numinus is ready for expansion. For more information on Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) and how the company is leading the integration of psychoactive-assisted therapies into mainstream clinical practice, please visit this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Numinus Wellness Inc. Market Jar Media Inc. has or expects to receive from Numinus Wellness Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) one hundred nine thousand four hundred and forty USD for 23 days (16 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Numinus Wellness Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc.’s industry; (b) market opportunity; (c) Numinus Wellness Inc.’s business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc.’s milestone projections and targets; (f) Numinus Wellness Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Numinus Wellness Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc.’s business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Numinus Wellness Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Numinus Wellness Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Numinus Wellness Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities. Contact Details Market Jar Media Inc. James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 23, 2022 06:30 AM Pacific Standard Time

Image

Better Brain Health and Parkinson’s Disease: Recognizing Symptoms, Taking Control of Your Health

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/m_aCzxxxWh4 Recent advancements in science show that there is so much you can do as you age to boost brain health. From diet and exercise to social connection, research is piecing together the puzzle of how to best care for your brain to help prevent neurological disease, and how to treat it if it develops. A newly expanded research study from the Michael J. Fox Foundation, The Parkinson’s Progression Markers Initiative (PPMI), is helping scientists better understand what it means to be at risk for brain diseases such as Parkinson’s. Through important contributions from study volunteers – via online questionnaires and at clinical sites around the country -- PPMI is revolutionizing what we know about Parkinson’s today. Would it surprise you to learn that new research points to long-term smell loss as a potential indicator of Parkinson’s? Or, that people who are recently diagnosed with Parkinson’s are the most valuable contributors to this groundbreaking research? There is so much being done to better understand, identify and treat Parkinson’s – the world’s second most common brain disease. And PPMI is helping the field get closer than ever to answering those questions. The Study That Could Change Everything PPMI is on a mission to understand who is at risk for Parkinson’s, who gets it and why. The study’s recent expansion means that anyone over age 18 can help, regardless of whether you have Parkinson’s disease or not. The more people who join PPMI and share valuable health data online, the faster we can change everything about how brain diseases like Parkinson’s are diagnosed, treated and ultimately, prevented. For more information, and to join PPMI, visit michaeljfox.org/ppmi Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 23, 2022 07:00 AM Eastern Standard Time

Video

RedBrick AI raises US$4.6M to accelerate the development of healthcare AI

Redbrick AI

Health-tech AI platform RedBrick AI is today announcing a US$4.6M seed funding round to accelerate the development and adoption of artificial intelligence in clinical settings, through rapid data annotation on medical imagery. The round was led by Surge, Sequoia Capital India, and Southeast Asia’s rapid scale-up program, with participation from Y Combinator and angels. Medical imagery is an essential source of truth in clinical diagnosis and comprises about 90% of all healthcare data. AI systems can dramatically shorten the time to diagnosis, improve clinician productivity by triaging high-importance cases, and act as the first line of defense in under-staffed clinical environments. Researchers and healthcare institutions are increasingly investing in AI solutions to improve diagnostics, treatment and patient quality of care. The use of AI in healthcare stands to transform patient care by boosting clinician productivity and automating clinical diagnosis. In 2021 alone, the U.S. Food and Drug Administration (FDA) approved 115 AI algorithms for use in medical environments, an 83% increase from 2018. However, researchers cannot use medical images to train AI systems until they are cleaned and expertly annotated. Training an AI system also requires hundreds of annotated medical images and thousands of hours of annotation by clinicians. Due to the complexity, size, and unique nature of medical images, clinicians have to resort to traditional and difficult-to-use clinical tools to perform annotations. RedBrick AI is thus laser focused on solving the first key challenge to healthcare AI adoption – providing clinicians high-quality data annotation tools that accelerate the preparation of training datasets. RedBrick AI CEO and co-founder Shivam Sharma commented: “Working with leading healthcare AI teams over the past year has been an incredible journey and learning opportunity. With the rapid growth of artificial intelligence in clinical settings, researchers need excellent tools to build high-quality datasets and models at scale. Our customers are in the vanguard of this growth, pioneering everything from surgical robots to automated detection of cancers. We are incredibly excited to use the funds we’ve raised to power the next generation of researchers in building AI for clinical settings.” RedBrick AI’s tools address several challenges unique to medical data annotation, such as the complexity of existing annotation tools, quality control and machine learning integration. The platform's specialized annotation tools can be accessed through the browser and are designed to be used without prior training. RedBrick AI also offers semi-automated tools to annotate complex 3D medical images. RedBrick has a robust quality control process to ensure the quality of annotations, which are crucial to securing AI algorithm certifications from regulators. It involves efficient quality control workflows on the platform that can compile the opinions of several clinicians per annotation case, all while dramatically reducing time spent on project management. Its API also helps machine learning engineers integrate with their cloud and clinical data stores, for example, AWS or hospital enterprise PACS servers. The APIs are used to build ML data pipelines. RedBrick AI launched in 2021 by CEO and co-founder Shivam Sharma, and CTO and co-founder Derek Lukacs. Both Shivam and Derek previously worked on SpaceX’s Hyperloop technology, and participated in the SpaceX Hyperloop Pod Competition. Shivam has a background in aerospace engineering and computer science from University of Michigan, while Derek holds a Bachelors and Masters in aerospace engineering from the University of Michigan. About RedBrick AI Teams building medical imaging AI use RedBrick AI to rapidly and collaboratively build high-quality training datasets. The RedBrick AI SaaS platform offers high-performance web annotation tools for 2D and 3D data to give experts access to specialized tooling right from their browsers. The RedBrick configurable workflow system helps teams build robust and scalable quality assurance processes. RedBrick AI offers a suite of APIs to help developers consume the annotations being created, and integrate with MLOps. For more information on RedBrick AI, visit https://redbrickai.com/ About Surge Surge is Sequoia Capital India and Southeast Asia’s rapid-scale up program. Surge combines up to USD 3 Mn of seed capital with company-building workshops, a global curriculum and support from a community of exceptional mentors and founders. The program’s goal is to supercharge early-stage startups in India and Southeast Asia and give founders an unfair advantage, right out of the gate. For more information on Surge, visit www.surgeahead.com. About Sequoia Capital India and Southeast Asia Sequoia helps daring founders build legendary companies, from idea to IPO to beyond. Sequoia Capital India and Sequoia Capital Southeast Asia actively partner with founders from a wide range of companies, across categories, including BYJUs, CRED, Druva, Five Star Finance, Freshworks, GoTo, Groww, Kopi Kenangan, Mamaearth, Pine Labs, Polygon, Razorpay, Truecaller, Zomato and more. We spur founders to push the boundaries of what's possible. In partnering with Sequoia, startups benefit with over 50 years of tribal knowledge and lessons learned working with companies like Airbnb, Alibaba, Apple, Dropbox, Google, LinkedIn and Stripe early on. From the beginning universities, endowments, and other non profits have been the backbone of our investor base which means founders' accomplishments make a meaningful difference. For more information on Sequoia's work in India and Southeast Asia visit sequoiacap.com/India and sequoiacap.com/sea. Contact Details Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://redbrickai.com/

November 23, 2022 06:00 AM Eastern Standard Time

Image

OTCMKTS : OCEL 📋 Organicell Starts Enrolling Long COVID Trial 😷

Organicell Regenerative Medicine, Inc.

Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

November 22, 2022 11:33 AM Eastern Standard Time

Video

AiViva’s Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs

AiViva BioPharma

AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases. AiViva has created a diverse product pipeline powered by its proprietary technology and new and innovative treatments. It has built a strong patent position to protect products to be commercialized for worldwide sales from its diverse product pipeline for ophthalmology, dermatology, urology, and oncology. The company has a veteran management team with a combined 300 years of experience at its helm. The California-based company has raised $30+ million in capital, including $10 million in 2022, and is buzzing with action and optimism. It boasts a robust clinical pipeline focused on wet, age-related macular degeneration (wAMD), prostate disorders, and nonmelanoma skin cancer. How AiViva’s Proprietary JEL™ Technology Works AiViva’s proprietary JEL™ technology is aimed at prolonging the therapeutic effects of drugs and enhancing their benefits. A key outcome of this strategy is a reduction in treatment frequency and systemic toxicity, which relieves patients of multiple visits to the doctor while gaining improved outcomes. AiViva’s JEL™ technology allows for the placement of the drug directly at the site of disease, where it forms a drug-infused mass or drug depot for prolonged drug release. Its delivery medium is a liquid at room temperature. When it’s injected into the diseased tissue at a warmer body temperature, it quickly hardens into a gelatin-like mass. This drug-infused gelatin serves as a storehouse, releasing the drug for release over time. The company says its JEL™ delivery platform offers customizable drug release and treatment duration for different therapies, making it a versatile drug delivery platform for the treatment of many major diseases, including solid tumors and wAMD. AiViva’s current focus is wAMD, and it’s set to begin clinical trials using its AIV007 compound combined with JEL™ in 2023. wAMD is a chronic eye disorder that causes blurred vision or a blind spot caused by abnormal blood vessels that leak fluid or blood into the macula — the area of the eye that provides the sharp, central vision needed for reading, driving and seeing fine detail — and scars it over time. Current treatments for this disorder only address the abnormal blood vessel growth (neovascularization) — not the formation of scar tissue or fibrosis. Leaving the scar tissue untreated could result in irreversible vision loss. There is no cure for wAMD. AiViva says its novel compound AIV007 embedded in JEL™ offers superior outcomes for wAMD because it targets neovascularization and addresses cell proliferation and fibrosis (scarring), improving impaired vision or preventing vision loss. In addition, AIV007 in JEL™ delivers localized and precise treatment, unlike most medicines that spread throughout the body randomly. AiViva’s technology only requires placing a tiny amount of drug at the disease site and ensures the drug remain there for a long treatment effect. This precision medicine would achieve good therapy outcome without annoying side effects, reduce the number of doctor’s visits. A Technology Backed By Patents That Could Be Applicable In Multiple Disease Treatments Applying the principles of its JEL™ technology, AiViva is targeting other major diseases that involve neovascularization, abnormal tissue growth and fibrosis, including benign prostate hyperplasia (enlargement of men’s prostates), low-grade prostate cancers and skin disorders. AiViva has ongoing clinical trials in skin cancer and keloid scarring for the compound AIV001. It has wAMD lined up as its next candidate for clinical trials. The indications targeted by AiViva represent a combined multi billion revenue potential, according to the company. The technology is protected beyond 2040 by patent applications in major markets, including Europe, Japan, China and the U.S. The company reports allocating almost 80% of its capital to research and development in the past years, through which it has been able to bring several projects through Food and Drug Administration’s (FDA) Investigational New Drug Applications (INDs). A Seasoned Management Team AiViva’s website highlights a management team of highly experienced industry experts with successful track records in drug development and commercialization. Its board members have been described as having led successful initial public offerings (IPOs) on the New York Stock Exchange (NYSE) and the Nasdaq Stock exchange. Here’s a look at some of them: Co-Founder and CEO Diane Tang-Liu held several senior executive positions at Allergan Plc. (NYSE: AGN), leading research and development (R&D) programs for over 30 years. Director Johnson Lau is CEO of Athenex Inc. (NASDAQ: ATNX) and was chair of the $75 million Athenex IPO in 2017. Johnson was previously CEO of Ribapharm Inc. (NYSE: RNA), which launched a $299 million IPO on the New York Stock Exchange in 2002 — the second-largest biotech IPO in history at the time. Director Larry Hsu was co-founder, president and CEO of Impax Laboratories Inc. (NASDAQ: IPXL), a company that had a market cap of about $3 billion at the time of his retirement. Director Jinn Wu was Dr. Jinn Wu is the Founder and President of XenoBiotic Laboratories, Inc. (XBL) in Plainsboro, New Jersey, and XBL-China in Nanjing, China. WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), acquired XenoBiotic Laboratories, Inc. With an impressive team leading the charge at AiViva, the company is optimistic about its ability to raise capital and believes its investors could reap high returns on their investment if the past experience of its collective leadership in leading IPOs is anything to go by. To learn more about AiViva visit the company website. To invest in AiViva go here. AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzingaâs in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuerâs securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. Contact Details Michael office@aiviva.com Company Website https://aiviva.com/

November 22, 2022 08:00 AM Eastern Standard Time

Breaking the Stigma Around Obesity and Weight Loss Medication

YourUpdateTV

There is a long history of stigma surrounding obesity and weight loss medications. When diet and exercise don’t lead to effective weight loss, sometimes it’s our biology that’s holding us back. Recently, Dr. Rekha Kumar, Head of Medical Affairs at Found, conducted a satellite media tour to talk about personalized weight loss and its benefits. A video accompanying this announcement is available at: https://youtu.be/qUhnxU91uPY Science shows that our biology can dictate up to 70% of weight gain, loss, and maintenance — yet the weight loss industry still reduces a person’s success to diet, exercise, and willpower. A variety of biological factors like genetics, hormones, metabolic rate and others contribute to our body’s “setpoint weight,” which is a certain weight that your body favors that is usually at the higher end of the scale. Your body wants to stay at this weight and fights hard to keep you there, and will even lower your metabolism or amp up your hunger signals to get back to your set point weight. Blaming obesity on a lack of willpower can take a psychological toll, causing people to feel shame, guilt, frustration or judgment, and fail to address biology as the core issue. Why Prescription Medication for Weight Loss? Obesity is a complicated disease that affects 40% of the US population, and it takes a personalized approach to each individual’s biology to treat it. Prescription medication can help people lose weight by fighting against their biology. Some medications work by suppressing appetite, and others work by curbing cravings. Weight loss medications have different mechanisms, and a doctor will have to evaluate if you're a good candidate for any of them. Not every medication is right for every person, and it’s common that if one doesn't work, a clinician might recommend trying a different medication. Historically, clinical care pathways for obesity management have only been available for patients at premiere academic medical centers, and typically have long wait lists. The Found’s program addresses a clear gap in access to weight care: Today, more than 40% of Americans have obesity, and yet only 1% of physicians specialize in obesity medicine. The medications Found offers are supported by clinical evidence to be highly effective and safe for helping aid with weight loss. Found has seen that members receiving medication plus behavior change support on the Found program have lost at least 13% more weight, and in some cases up to 229% more weight, than people receiving the same medication in clinical studies. Found is the largest online weight care clinic in the country, helping more than 160,000 Americans with their weight loss journey to-date. Found offers 13 different medications that can be combined to create more than 60 different possible treatment paths, available through their Prescription Program, each uniquely paired to address a person's biological and medical history. Found’s wide toolkit of medications fundamentally helps to serve a broader audience than others in the space. The Practice of Responsible Prescribing Found-affiliated providers are trained in the Found treatment protocol, which looks at various factors to determine the medication that will be safest and most effective for a member’s individual needs.Found-affiliated practitioners prescribe both FDA-approved branded anti-obesity medications as well as off-label generic combinations when determined safe by the treating clinician. The medications prescribed are the same medications that are offered in premiere academic medical centers.Treatment through the Found platform expands access to obesity treatment by bypassing long waitlists for appointments and copays for visits at in-person clinics. Found-affiliated medical providers are expected to always provide treatment and care that is in the best interest of their patients. For more information on Found’s weight care program, please visit joinfound.com Bio for Dr. Rekha Kumar, M.D., M.S. Dr. Rekha Kumar is recognized as an international leader in the field of Obesity Medicine. She is Head of Medical Affairs at weight care platform Found, as well as a practicing endocrinologist at an academic medical center in New York City. She also served as the former medical director of the American Board of Obesity Medicine. Dr. Kumar has lectured internationally on the topic of the medical assessment and treatment of obesity. She has published several papers and textbook chapters in her field and serves as an Associate Editor of the journal Obesity. She is frequently quoted in the media on topics ranging from the diabetes epidemic in the United States to discussing fad diets, exercise trends, and the complications of Covid-19 in patients with obesity. Dr. Kumar’s areas of expertise include the clinical assessment of patients with obesity and metabolic syndrome, the effect of obesity on reproductive health and fertility, and thyroid disease. Dr. Kumar completed her undergraduate studies at Duke University then received her master’s degree in Physiology from Georgetown University. She continued on to receive her M.D. from New York Medical College and completed her residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the Weill-Cornell Medical College/New York Presbyterian Hospital and the Memorial Sloan Kettering Cancer Center. Dr. Kumar has traveled abroad to India, China, and Tanzania to understand the scope of metabolic disease globally. She serves on the board of advisors of the Duke Global Health Institute. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 22, 2022 07:00 AM Eastern Standard Time

Video

Synchrony “Lifetime of Healthcare Costs” Study Indicates People Underestimate Cost of Care Significantly

YourUpdateTV

Click to view video featuring Jean Chatzky: https://youtu.be/-nGhkeAo0G8 Are You Saving Enough for Future Healthcare Expenses? New research from Synchrony’s “Lifetime of Healthcare Costs” Study reveals the average individual insured Americans cost of out-of-pocket healthcare costs from age 18 to the average life expectancy of age 79. Many of us save for significant costs, such as a home mortgage, a new car, or college tuitions. But when it comes to our own health – which should be the most important thing to take care of – we don’t take under consideration how much we pay annually outside of what is covered by insurance. Jean Chatzky conducted a nationwide media tour in partnership with Synchrony to provide real world advice and steps to help bridge the clear gap between people’s perceptions and the reality of the costs of healthcare today. During radio and TV interviews across the country, Jean Chatzky discussed: What the recent survey said about the cost of healthcare Surprising results from the survey Why it is so important for Americans to understand these out-of-pocket healthcare costs Valuable resources people can use to help manage these costs For more information visit: carecredit.com/lifetime-study/ Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 21, 2022 02:00 PM Eastern Standard Time

Video

The Chicago School of Professional Psychology Trustees Join Homeless Outreach

The Chicago School of Professional Psychology

Emphasizing that community service is “in the DNA” of The Chicago School of Professional Psychology, a dozen members of its Board of Trustees last week participated in an outreach project to benefit unhoused people in Los Angeles. About 600 kits, including blankets and personal care items, were collected, boxed and hand-delivered to residents of Los Angeles’ Skid Row, according to Dr. Nadia Rojas Jones, the faculty member who has organized the annual effort with students from the school’s three Southern California campuses for the past seven years. “We are here to show our support of faculty and students in their efforts to help underserved populations, whether it’s those without permanent shelter or in communities of color or people with low income,” said Terrence Joe Layng, Ph.D., Chair of the Board of Trustees. “The commitment to community service is what differentiates The Chicago School-- our students and faculty are deeply involved in the communities they serve,” said Trustee Victoria Dolan, former CFO of Revlon. Every year, The Chicago School’s students provide 1.2 million volunteer service hours in 600 organizations across the United States, according to Dr. Michele Nealon, Psy.D. “There are nearly 70,000 unhoused individuals in Los Angeles County today, a four percent increase from two years ago,” she said. “We know that many of them have mental health issues that are going undiagnosed and untreated.” The Chicago School of Professional Psychology, a non-profit higher education institution headquartered in Los Angeles, serves 6,000 students on seven U.S. campuses (including online). Two-thirds of the student body identifies as people of color. # About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 21, 2022 07:00 AM Pacific Standard Time

Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

Destiny Pharma PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 21, 2022 09:19 AM Eastern Standard Time

Video